@author-1788515151757110
In the field of neurodegenerative diseases, true technical breakthroughs don't come from the elegance of any single algorithm, but from the systematic deconstruction and reconstruction of the disease itself.
The ranking aims to reveal the actual exit performance of VC/PE funds and institutions, serving as a critical data benchmark for LPs to evaluate fund performance and institutional investment capabilities.
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Future Intelligent focuses on R&D and scenario innovation for AI-powered office hardware.
The ranking aims to offer an objective lens for understanding application trends in China's generative AI space, spotlighting early adopters and benchmark cases that dare to experiment and innovate.
Following Qiming Venture Partners' portfolio companies' milestone moments with you
As China's first independently developed gene therapy for hemophilia B, Xinjiuning® will offer patients a completely new treatment option, with the potential to free them from a lifetime of frequent intravenous injections and help them return to a life without constraints.
The ranking reflects the influence of China's private equity market in the global investment industry.
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
